Roth Capital Downgrades LB Pharmaceuticals to Neutral, Lowers Price Target to $35

Benzinga · 2d ago
Roth Capital analyst Boobalan Pachaiyappan downgrades LB Pharmaceuticals (NASDAQ:LBRX) from Buy to Neutral and lowers the price target from $37 to $35.